Save the Date BLE

 

Brand Licensing Europe, the leading licensing fair that will be held in London (Oct. 9-11) is approaching fast.

This year’s central theme of Food & Beverage Licensing is close to our heart and we have many exciting activities planned around it!

 

Tuesday 9th October, Happy Hour at the Chupa Chups booth L70

(5pm – 5.45pm):

Chupa Chups has reasons to celebrate. The brand turns sixty and has been licensed with success for twenty years. This calls for a celebration!

Come and join us for a drink and many fun surprises at the HAPPY HOUR in our booth.

 

Wednesday 10th October at the BLE Seminar Panel

“How to Build a Successful Food Licensing Programme”

(1.30pm – 2pm):

Don’t miss out on the expert panel lead by Beanstalk on “How to Build a Successful Food Licensing Programme”. Perfetti van Melle’s Christine Cool is joining Declan Hassett, Senior Brand Licensing Manager of Diageo as panellist, to focus on our food programmes and the mechanisms to secure quality and retail support.

“How to keep innovating with F&B brands in licensing”

(2.30pm – 3pm):

In a dedicated session to Perfetti van Melle’s licensing program “How to keep innovating with F&B brands in licensing”, Marta Ballesteros and Christine Cool will talk about the highlights and challenges in 20 years of lifestyle licensing with Chupa Chups, the recent diversification in F&B licensing and the brand expansion strategy.

 

Product Showcase

Look out for BLE’s Product Showcase area where the creativity and diversity of the show’s Brands & Lifestyle and Art, Design & Image exhibitors is displayed in a unique setting. Here you can see the 'one of a kind' star piece of Maya Hansen’s capsule collection with Chupa Chups, the stunning corset. 

 

We are looking forward to seeing YOU at the show!

PVM Licensing Division

www.pvmlicensing.com

newswirelogo

  • SHANGHAI, China, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that the first patient has been dosed in a Phase 1b/2 study evaluating FGF401 in combination with PD-1 inhibitor, pembrolizumab, in patients with advanced solid tumors, such as hepatocellular carcinoma (HCC).

  • 中国上海, Aug. 07, 2020 (GLOBE NEWSWIRE) -- 云顶新耀(Everest Medicines),一家专注于创新药开发及商业化的生物制药公司,致力于满足大中华区及其它亚洲市场未被满足的医疗需求,今日宣布在FGF401联合PD-1抑制剂Pembrolizumab用于治疗晚期实体瘤(例如肝细胞癌)的1b/2期临床研究中完成首例受试者给药。

  • HOUSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Houston Wire & Cable Company (NASDAQ: HWCC) (the “Company”) announced operating results for the second quarter ended June 30, 2020 and progress on its cost and debt reduction programs.

  • CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI), a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $15.00 per share. All of the shares are being offered by Checkmate. Checkmate’s common stock is expected to begin trading on the Nasdaq Global Market under the ticker symbol “CMPI” on August 7, 2020. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Checkmate, are expected to be approximately $75,000,000. The offering is expected to close on August 11, 2020, subject to the satisfaction of customary closing conditions. Checkmate has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

  • AUSTIN, Texas, Aug. 06, 2020 (GLOBE NEWSWIRE) -- ESW Capital, LLC (“ESW”) – confirms that it has delivered today an application to the Ontario Securities Commission (the “OSC”) for an exemption from the “majority of the minority” requirement contained in Section 2.29.1(c) of National Instrument 62-104 (the “Exemption”) in connection with its previously announced intention to make an offer to acquire any and all subordinate voting shares (the “Shares”) in the capital of Optiva, Inc. (TSX:OPT) (“Optiva”) at the price of CAD $60 per Share (the “Offer”).

Contact Us

Retail Merchandiser Magazine

Cringleford Business Centre,
Intwood Road Cringleford,
Norwich, UK, NR6 4AU

  +44 (0) 1603 274 130

Click here for a full list of contacts.

Back To Top